---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-037086"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:32:51.805674+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals' Corporate Controller resigns; CEO appointed as interim principal financial officer

## Summary
- Michael Meluzio resigned as Corporate Controller and interim principal financial/accounting officer on March 18, 2022.
- Brian M. Strem, Ph.D., President and CEO, appointed as principal financial and accounting officer effective March 18, 2022.
- Company engaged Danforth Advisors, LLC for interim finance and accounting services until a permanent replacement is found.
- Resignation not due to any disagreement with company's operations, policies, or practices.

## SEC filing metadata
- accession: 0001104659-22-037086
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000110465922037086/0001104659-22-037086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000110465922037086/tm2210197d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-037086
- JSON: https://secwatch.observer/filing/0001104659-22-037086.json
- Plain text: https://secwatch.observer/filing/0001104659-22-037086.txt

## Key facts
- Executive change
  Brian M. Strem was appointed as President and Chief Executive Officer at KIORA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Effective as of March 18, 2022, Brian M. Strem, Ph.D., the Company’s President and Chief Executive Officer, was appointed as the Company’s principal financial officer and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465922037086/0001104659-22-037086-index.htm
- Executive change
  Michael Meluzio resigned as Corporate Controller at KIORA PHARMACEUTICALS INC.
  - Action: resigned
  - Role: Corporate Controller
  source text: On March 18, 2022, Michael Meluzio resigned as the Corporate Controller of Kiora Pharmaceuticals, Inc. (the “Company”) to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465922037086/0001104659-22-037086-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.